On August 18, 2017, the President signed into law the Food and Drug Administration Reauthorization Act (FDARA), which includes a reauthorization of four of the medical product user fee programs, the Prescription Drug User Fee Amendments, Medical Device User Fee Amendments, Generic Drug User Fee Amendments, and Biosimilar User Fee Amendments. 

Three of FDA’s medical product center directors discuss importance of the FDA Reauthorization Act of 2017.

FDARA: Making a Difference for Industry and Patients